SCHEMBL6764979

SCHEMBL6764979

O=C(Nc1ccc(S(=O)(=O)CC(O)C(=O)NO)cc1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 2/20 0.57
KMT2A Q03164 5/20 0.55
MEN1 O00255 4/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
HPGD P15428 1/20 0.55
LMNA P02545 3/20 0.52
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
MMP9 P14780 4/20 0.49
MMP2 P08253 3/20 0.49
MMP1 P03956 1/20 0.49
MMP3 P08254 1/20 0.49
MMP8 P22894 1/20 0.49
MAPT P10636 2/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CACNA1B Q00975 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789136 0.80 KMT2A (0.50) PRMT1KMT2AMEN1CA12CA1
SCHEMBL5919480 0.79 MMP1 (0.64) PRMT1KMT2AMEN1CA12CA1
SCHEMBL6764875 0.77 MMP13 (0.70) MMP9MMP2MMP1MMP3
SCHEMBL6764872 0.77 MMP13 (0.70) MMP9MMP2MMP1MMP3
SCHEMBL6773916 0.77 MMP13 (0.74) MMP9MMP2MMP1MMP3MMP8
SCHEMBL6764610 0.77 MMP13 (0.70) MMP9MMP2MMP1MMP3
SCHEMBL7867105 0.74 KDM4E (0.68) PRMT1KMT2AMEN1CA12CA1
SCHEMBL6790742 0.73 KMT2A (0.53) PRMT1KMT2AMEN1CA12CA1
SCHEMBL6784814 0.73 PRMT1 (0.52) PRMT1KMT2AMEN1CA12CA1
SCHEMBL9711239 0.73 PRMT1 (0.63) PRMT1KMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716844-B2 ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS PHARMACIA CORPORATION 2004-04-06 US disclosed
EP-0984959-B1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2003-09-24 EP disclosed
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds PHARMACIA CORPORATION 2002-11-21 US disclosed
US-6362183-B1 PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS G. D. SEARLE & COMPANY 2002-03-26 US disclosed
EP-0984959-A4 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO CO (US) 2001-05-02 EP disclosed
EP-0984959-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-03-15 EP disclosed
WO-1998039326-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds MMP1, MMP2, MMP3 PRMT1 4132/4885KMT2A 986/4885MEN1 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.